Log In Get Started
Press Releases May 21, 2026 04:15 PM

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics to Present at Jefferies and Leerink Investor Conferences in 2026

By Avery Klein TRAX

First Tracks Biotherapeutics, a clinical-stage biotech company focused on antibody therapeutics for autoimmune and inflammatory diseases, announced its participation in upcoming investor conferences hosted by Jefferies and Leerink Partners. The company plans to present its clinical pipeline progress and engage in investor meetings in June and July 2026.

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
TRAX

Key Points

  • First Tracks Biotherapeutics is advancing antibody therapies targeting autoimmune and inflammatory diseases, with key pipeline candidates including ANB033, rosnilimab, and ANB101.
  • Company executives will present and hold one-on-one meetings at major investor conferences, increasing visibility among healthcare investors.
  • These activities aim to update the investment community on clinical development progress and potential future milestones in immune modulation therapies.

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

2026 Jefferies Global Healthcare Conference, New York

  • Format – Presentation and one-on-one investor meetings
  • Date and Time – Wednesday, June 3, 2026 at 12:15pm ET / 9:15am PT

Leerink Partners Therapeutics Forum, Boston

  • Format – One-on-one investor meetings
  • Date and Time – Tuesday, July 14, 2026

A live webcast of the presentation will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events. A replay of the webcast will be available for at least 30 days following the event.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Investor Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]


Risks

  • Clinical-stage development inherently comes with risks related to clinical trial outcomes and regulatory approvals, which can impact future success and valuation.
  • The company operates in the competitive biotechnology sector focused on autoimmune diseases, where scientific and market challenges remain significant.
  • Market response to conference presentations may be limited if no new material data or milestones are disclosed, keeping stock volatility possible.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Telesat announces results of 2026 Annual General Meeting of shareholders Jun 4, 2026 TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology Jun 4, 2026 Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026